Berberine, often touted as a weight loss and liver "cleanser," does not help reduce visceral fat and liver deposits. This was revealed in a study published in JAMA Network Open.
The multicenter, randomized, double-blind study involved 337 adults who had obesity and metabolic-related fatty liver disease but no diabetes. One group took berberine and the other a placebo for six months. The researchers assessed changes in visceral fat and liver fat content using computed tomography (CT).
The results showed that there were no significant differences between the groups. Participants taking berberine had virtually no change in visceral fat, while the proportion of liver fat even increased slightly. In contrast, the placebo group showed a small decrease in these parameters.
At the same time, the researchers noted a moderate effect of berberine on certain biochemical markers. Those taking the supplement had lower levels of "bad" cholesterol (LDL), apolipoprotein B, and some inflammatory markers. However, these changes were not accompanied by a decrease in body fat.
Scientists have noted that berberine is a pharmaceutical agent that has choleretic and antispasmodic effects. It is most often obtained by processing the root of the Hydrastis canadensis plant.
According to the study authors, berberine may have a limited effect on lipid profile and inflammation, but does not address the underlying problem of excess body fat, which is important to consider when choosing treatment and prevention methods.
Translation: Euromedia24.com-in:
